These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
620 related articles for article (PubMed ID: 21270143)
1. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH; Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143 [TBL] [Abstract][Full Text] [Related]
2. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. Barnett PG; Scott JY; Krystal JH; Rosenheck RA; J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193 [TBL] [Abstract][Full Text] [Related]
3. [Pharmacoeconomic review of the use of injectable long-acting risperidone]. Bartkó G; Fehér L Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329 [TBL] [Abstract][Full Text] [Related]
5. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Keith S Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665 [TBL] [Abstract][Full Text] [Related]
6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343 [TBL] [Abstract][Full Text] [Related]
8. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
9. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine]. Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790 [TBL] [Abstract][Full Text] [Related]
11. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981 [TBL] [Abstract][Full Text] [Related]
12. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA; J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A; Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986 [TBL] [Abstract][Full Text] [Related]
15. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia? Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207 [TBL] [Abstract][Full Text] [Related]
16. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752 [TBL] [Abstract][Full Text] [Related]
17. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474 [TBL] [Abstract][Full Text] [Related]
18. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Li H; Rui Q; Ning X; Xu H; Gu N Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787 [TBL] [Abstract][Full Text] [Related]
19. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia]. Faludi G Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464 [TBL] [Abstract][Full Text] [Related]
20. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study. Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):61-8. PubMed ID: 22776632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]